Targeted Osmotic Lysis
Oleander Medical Technologies is developing a revolutionary new treatment to destroy many of the most invasive and deadly cancers using a process called Targeted Osmotic Lysis (TOL).
Intro to TOL
Since 1998, Dr. Dennis Paul and Dr. Harry Gould of Louisiana State University have been studying basic cell function, with special focus on how sodium channels respond to disease. Their findings have allowed them to take advantage of a previously known property of malignant cancer cells to devise a safe and effective treatment for many of the deadliest cancers: Targeted Osmotic Lysis (TOL).
How TOL works
Advanced-stage cancer cells express 10 to 50 times more sodium channels in their cell membranes than do normal cells. By stimulating the opening of these channels and enabling the entry of large amounts of sodium while blocking the mechanism to expel the excess ions, Dr. Paul and Dr. Gould have been able to force cancer cells to burst, while leaving healthy cells unharmed. The treatment process uses a generic drug used to treat heart ailments (digoxin) and a new device that produces a pulsed electric field.
Why the world needs TOL
Learn why so many cancer cases are beyond the reach of current conventional treatments, and how TOL could potentially save hundreds of thousands of lives every year.
All about the procedure
Access more specific information on Targeted Osmotic Lysis, including details regarding the pump-blocker drug, the electrical device, and the treatment process.
Our path so far
Track the development of TOL and learn about our next steps moving ahead.
The people behind the project
Get to know the extraordinary individuals working to make Targeted Osmotic Lysis a reality.
Latest information
Check out the most recent updates from our journey forward.
Subscribe for updates
Sign up with your email address to receive news and updates from Oleander.
We respect your privacy. Your personal information will not be shared in any way.